Loading organizations...
Learn which startups Third Rock Ventures invests in, what size check sizes they write, and who their partners are (e.g. Robert Tepper).
Get email updates
Join 25K+ founders & VCs who start their week informed.
Third Rock Ventures is a healthcare venture firm that builds new life sciences companies from inception. They discover, launch, and develop innovative enterprises by integrating bold scientific concepts with strategic business and medical expertise. The firm provides comprehensive operational support, fostering robust corporate cultures for these nascent ventures.
Established in 2007 by experienced life sciences leaders, many from Millennium Pharmaceuticals, the firm originated from a market insight. They identified a need for a dedicated, hands-on company creation model in biotech given cautious traditional venture capital. This founding philosophy prioritized translating scientific discoveries into viable therapeutic solutions.
Companies fostered by Third Rock Ventures aim to develop transformative medicines that profoundly enhance patients' lives. The firm’s vision is to be the preferred partner for entrepreneurs and industry, establishing enterprises focused on advancing novel therapeutics. They aspire to contribute to a future where scientific innovation addresses critical unmet global medical needs.
Key people at Third Rock Ventures.
Third Rock Ventures is a leading healthcare venture capital firm with a mission to build innovative life science companies that transform patient lives. Its investment philosophy centers on identifying bold scientific ideas and translating them into breakthrough medicines, with a focus on unmet medical needs in areas like cancer, rare genetic disorders, immune disorders, and neurodegenerative diseases. The firm specializes in biotechnology, pharmaceuticals, and medical devices, and is known for its hands-on approach to company creation—actively shaping startups from inception through growth. Third Rock has played a pivotal role in the biotech ecosystem, launching more than 60 companies and bringing 16 products to market, many of which have been acquired or gone public.
Founded in 2007 and headquartered in Boston, Third Rock Ventures was established by a group of seasoned life science entrepreneurs and investors with deep roots in both academia and industry. The firm’s early years were marked by a deliberate focus on building companies from the ground up, rather than simply funding existing ventures. Over time, Third Rock evolved into a premier partner for scientists and entrepreneurs, leveraging its network and operational expertise to launch and scale transformative biotech startups. Its reputation for generating strong returns—tripling investors’ money on average—has cemented its status as a top-tier venture firm in the biotech sector.
Third Rock Ventures is at the forefront of the biotech revolution, riding the wave of rapid advances in genomics, immunology, and precision medicine. The timing is critical, as the healthcare sector faces growing demand for innovative treatments and more efficient drug development. By fostering collaboration between scientists, clinicians, and entrepreneurs, Third Rock helps accelerate the translation of cutting-edge research into real-world therapies. Its influence extends beyond individual companies, shaping the broader ecosystem by setting new standards for venture-backed biotech and inspiring a generation of life science startups.
Third Rock Ventures is poised to remain a dominant force in biotech venture capital, with its latest fund fueling the next wave of innovation. As the boundaries between science and medicine continue to blur, the firm’s ability to identify and nurture transformative ideas will be more valuable than ever. The future will likely see Third Rock expanding into emerging fields like in vivo genome editing and digital health, while continuing to drive breakthroughs that improve patient outcomes. Its legacy as a builder of life-changing companies is secure, and its impact on the biotech landscape will only grow in the years ahead.
Key people at Third Rock Ventures.
Third Rock Ventures has more than 26 tracked investments across 20 companies. The latest tracked deal is $165.0M Series A in Syremis Therapeutics in December 2025.
